Breaking Research News from sources other than Breastcancer.org
Comments
-
Dear Saulius, please don’t apologize, your posts are very helpful and full of good information. And yes, you stay so well informed that you do sound like an oncologist! I am a HER2+ gal also - so all HER2 positive posts are of interest to me. Just the fact that the experts will discuss treating any of us with curative intent is very exciting. I wonder if the Dana Farber study has begun? I see Dr Winer mentioned the 77 patients, it seems to be referring to the planned study on the slide you posted
Kanga_Roo - interesting article. I just happened to come across this paper a few days ago “Hyperglycemic Conditions Proliferate Triple Negative Breast Cancer”
https://www.researchsquare.com/article/rs-520490/v1
It’s a preprint so not peer reviewed yet and it’s just about cells in a Petrie dish but still interesting.
0 -
Dear Olma, thanks a lot for your kind words. It'd be absolutely great if anyone who "attends" Dana Farber, or anyone in Boston, or Massachusetts, or even USA, could ask what is the state of that "possible" trial or trials similar like these? Of course, usually I wait for half a year/one year after something was announced I write and ask. I wrote really to quite a few top oncologists around the world and, to my surprise, got every and each answer. Extremely kind and understanding people. As close to top developments as one can get - trial and clinic wise. Just give them concrete questions, and you'll get all your answers. So dr. Parsons and dr. Lin, you still have half a year until Saulius' letter comes!:)
0 -
Saulius,
I have to echo what you've said. I've sent questions to a number of docs and they do respond, especially if you send very specific questions. They have always been kind.
And I do have to laugh about when your next few letters will be going out!
0 -
Phase 3 trial: ultra high single dose radiation was superior to 3 SBRT tx for oligomets
https://doi.org/10.1016/j.ijrobp.2021.01.004
edit: oops ok for reasons I don't understand I can't get the link to work but I think if you copy & paste this into a browser it should work redjournal.org/article/S0360-3016(21)00006-7/fulltext
"The study confirms SDRT as a superior ablative treatment, indicating that effective ablation of oligometastatic lesions is associated with significant mitigation of distant metastatic progression."
0 -
Moth, sounds like a good finding but I think the link is off somehow unless I’m the problem, which is entirely possible, lol. Would you mind checking, if you have time?
0 -
argh, I fought with that link 3 times and thought I'd outsmarted it with the DOI link instead but I guess not!
I'm editing it now one more time...
0 -
Thanks Bev, it is very nice to see you back here!:) Also, an ASCO summary on her2 ADCs in trials for her2low - looks very very promising! Saulius
0 -
That's great news for those with HER2-low MBC. The drug SYD 985 ( trastuzumab duocarmazine)already finished phase 3 trials for HER2+ (not low)and should be coming to market soon.
0 -
"Tamoxifen treated BC patients showed a reduced rate of hospitalization and strikingly no fatalities for COVID-19. In vitro experiments confirmed a protective role of tamoxifen while an increased susceptibility to SARS-CoV-2 infection of ER+ cells treated with fulvestrant was observed".
0 -
Olma61 - I loved the video about bones. I was so encouraged that I stopped by the gym on the way home to lift weights. I’m also increasing my walking. Thank you!
0 -
Oh, you’re very welcome! Happy to see this,
0 -
Olma61 and GoKale3420, which video is the bones video? Can't find it.
0 -
The link I posted was actually in the Bone Mets thread under Stage IV - here's the link on YouTube, might also be on lbbc.org
0 -
Thanks for Sharing that bone info. That was really educational and helpfu
0 -
YW and yes, I thought it was so comprehensive, whether for newly diagnosed or or “seasoned” metsters.
By the way, have not seen Lumpie, the OP of this thread posting lately and her last activity shows as May 7th. Hope she is okay, does anyone know her
0 -
Lumpie sometimes takes a breather for several weeks, just to recharge, so hopefully that’s what’s going on.
0 -
Lumpie, we appreciate you and this super-valuable thread!! Love to you!
0 -
You are so kind to be concerned. Doing ok here! Taking a bit of a breather, visiting some fully vaccinated family at long last, stopping off for some R&R and doing advocacy around access to health care. Plus sometimes I just get in a rut and feel like I read the same studies over and over ... you probably know what I mean ... though I did see something a couple of days ago I thought I should post. As soon as I find it among my billion emails, I will pass it along. Thanks, all! Take care and be well. -Lumpie
0 -
Glad you popped in Lumpie. I really appreciate this thread. Glad you are out there living life!
0 -
Yes, good to hear from you! Enjoy th well-deserved R and R , thanks for checking in
. 0 -
Consequences of DDT Exposure Could Last Generations
DDT continues to haunt human bodies. In earlier studies, she found that the daughters of mothers exposed to the highest DDT levels while pregnant had elevated rates of breast cancer, hypertension and obesity.
Cohn's newest study, on the exposed women's grandchildren, documents the first evidence that DDT's health effects can persist for at least three generations. The study linked grandmothers' higher DDT exposure rates to granddaughters' higher body mass index (BMI) and earlier first menstruation, both of which can signal future health issues.
Nice synopsis here: https://www.phi.org/press/consequences-of-ddt-expo...
Read the PHI press release on the study here.
{Study} ORIGINALLY PUBLISHED BY Scientific American
Also reported in Cancer Epidemiology, Biomarkers, and Prevention
https://cebp.aacrjournals.org/content/early/2021/0...
DOI: 10.1158/1055-9965.EPI-20-1456
{Journal article requires subscription or fee. Others should be accessable without charge.}
0 -
New study will begin enrolling third quarter of 2021 - for Metastatic Triple Neg
testing Agents to boost Trodelvy action
Open label Phase 1b/2
"Open-label Phase 1b/2 study will evaluate the safety and preliminary efficacy of Anktiva (N-803) and PD-L1 t-haNK in combination with antibody-drug conjugate Trodelvy and low-dose chemotherapy in subjects with advanced triple-negative breast cancer (TNBC) after prior therapy"
0 -
Study finds breast cancer's response to tumor stiffness may predict bone metastasis
Tumor stiffening, which develops as diseased breast tissue becomes fibrotic, plays a major role in how breast cancer cells spread throughout the body. The paper, "Breast tumor stiffness instructs bone metastasis via maintenance of mechanical conditioning," published today in the journal Cell Reports, found that the stiffness of the breast tumor microenvironment can cause changes to cancer cells that make them more aggressively spread to the bone. The resulting changes are maintained as "mechanical memory," which instructs the cancer cells to send signals that lead to the breakdown of bone. Once this happens, patients often suffer debilitating complications like spontaneous fractures...
The study, which is the first to demonstrate the concept of mechanical memory during cancer metastasis, developed a novel mechanical conditioning, or "MeCo," score, to quantify the cellular changes. Eventually, researchers hope the MeCo score can be used to help identify breast cancer patients who might benefit from repurposed antifibrotic treatments to prevent bone metastasis.
0 -
[Early research] New discovery could yield a potential new treatment for breast cancer
In a study published this month in Cell Reports, the team used small molecules known as peptides to disrupt a complex of two proteins, RBM39 and MLL1, that is found in breast cancer cells but not in normal cells.
The research team discovered that the abnormal interaction between RBM39 and MLL1 is required for breast cancer cells to multiply and survive. The team developed non-toxic peptides that prevent these proteins from interacting in breast cancer cells, disrupting their growth and survival.
https://www.news-medical.net/news/20210629/New-dis...
0 -
[Early research] RNA-binding proteins represent a new class of drug targets for triple-negative breast cancer
The researchers systematically silenced RNA-binding proteins in these cancer cells one-by-one using the CRISPR gene editing technique. They found 57 RNA-binding proteins that, when inhibited, kill cancer cells with the known hyperactive cancer-driver. The advantage of the synthetic lethal approach is that normal cells, which don't produce that cancer-driving molecule, should be left untouched by the treatment. Of these 57 RNA-binding proteins, YTHDF2 appeared most promising...
The researchers [got a] detailed look at how the various cells that make up a breast tumor behave without YTHDF2. The approach revealed that YTHDF2-deficient cancer cells die by stress-induced apoptosis, a carefully controlled mechanism cells use to destroy themselves. Apoptosis is supposed to shut down malfunctioning cells so tumors don't arise, but it doesn't always work. By removing YTHDF2, they managed to re-activate this cell death signal.
To test how safe it might be to treat cancer by inhibiting YTHDF2, the researchers engineered mice that lack YTHDF2 in every cell of the adult body, not just transplanted breast cancer cells. The mice appeared completely normal -- not only did they not have tumors, there were no changes in body weight or behavior.
0 -
ddebbew - I saw where RNA may help with cancer, I didn't see which kind. That's great news, now if it only helped ALL cancers
0 -
HomeMom,
I had the wrong link for the last article I posted. I've fixed it now. The testing was done on TN BC using human cells and mouse models. The study identified an RNA-binding protein which was needed for the cancer cells to survive but not needed by normal cells. The next step would be to target this protein with a drug.
ETA: Here's a more detailed article that came out today: https://www.genengnews.com/news/rna-binding-protei...
0 -
I found this article very interesting:
Seed and Soil: Tracing the Journey of Spreading Cancer Cells
0 -
Oral paclitaxel may still be a future option despite being denied FDA approval a few months ago. "The FDA was supportive and encouraged the Company to continue development of oral paclitaxel and encequidar for the treatment of metastatic breast cancer. The FDA also agreed that a well-designed and well-conducted trial may adequately address the deficiencies raised in the CRL." https://www.obroncology.com/news/athenex-provides-update-from-fda-type-a-meeting-regarding-oral-paclitaxel?ap=334&vhid=
Interesting article LIllyishere
0 -
this sounds interesting - early trials
0
